Please enter your details to request more information

Invest in the bio-pharmaceutical company, revolutionising the medicinal cannabis world

  • Private Share Price: $0.25
  • Forecasted Public Share Price: $5.

212% growth forecast by 2029. *

Plant-based neurotherapeutics are vital in the care of cancer, pain management and opioid replacement. We produce & supply these vitally needed, pharma-grade medicines at scale, to meet the staggering global demand.

  • Fully Licenced
  • SEC Reporting
  • Vertically Seed-to-Patient operating model
  • The global regulated medicinal cannabis market set to be worth US$54.3 billion by 2029
  • SAHPRA-licensed, pharmaceutical grade cultivation and GMP focused production
  • Strategic expansion via US, South Africa and Australia

CINV is a pioneering medicinal cannabis company specialising in cultivating and distributing cannabis-based products for medicinal use (CBPMs). We are dedicated to exploring and advancing therapeutic cannabis genetics with full-spectrum terpenes and cannabinoids.

The CINV Roadmap

  • 2,200 Kilograms of medicinal cannabis currently produced per year, forecast target of 9,000+ kilograms per year by 2029.
  • Public Listing
  • CINV Corp EBITDA Margin Expands From 24% in 2026 to 42% in 2029.

*Based on Gross Profit. Download the Investment Memorandum for full financial forecasts.

To be able to deal with your enquiry effectively we will need to contact you via telephone and/or email. By enquiring you consent to being contacted and you consent to your data being stored in accordance withEuropean GDPR regulations. Privacy Policy


Disclaimer: Any person accessing this website or page and considering potential investment opportunities featured here, should make their own commercial assessment of an investment opportunity after seeking the advice of an appropriately authorised or regulated financial advisor. This website or page should not be construed as advice or a personal recommendation to any prospective investor. Investments of this nature carry risks to your capital and can go up or down. Past performance is not indicative of future results. Suitable appropriately qualified investors, sophisticated and high net worth investors only.